Active Filter(s):
Details:
Ascentage Pharma and the NCI will collaborate on a series of clinical trials to evaluate the safety and efficacy of pelcitoclax, Ascentage Pharma's dual inhibitor of BCL-2 and BCL-xL proteins, in solid tumors based upon encouraging anti-tumor activity.
Lead Product(s): Pelcitoclax,Paclitaxel
Therapeutic Area: Oncology Product Name: APG-1252
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Ascentage Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 19, 2021
Details:
Company is going to present four posters of the latest clinical data on three of its drug candidates, including the MDM2-p53 inhibitor APG-115, novel Bcl-2/Bcl-xL dual inhibitor palcitoclax or APG-1252, and IAP inhibitor APG-1387.
Lead Product(s): Pelcitoclax
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2020